ArticleClinical and experimental nephrology2026
Nationwide epidemiological survey of autosomal dominant polycystic kidney disease in Japan in 2022.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Healthcare burden and clinical spectrum of symptomatic polycystic liver disease in Japan: a nationwide epidemiological survey.Journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAccurate epidemiological data on autosomal dominant polycystic kidney disease (ADPKD) are essential for healthcare planning and therapeutic strategies. However, nationwide prevalence estimates in Japan have not been updated for decades.
methodsThis was a nationwide survey conducted in Japan. Departments at hospitals were selected using stratified random sampling based on specialty and hospital size. The number of patients with ADPKD not receiving kidney replacement therapy (KRT), defined in this study as those who did not receive dialysis and did not newly undergo kidney transplantation in 2022, was estimated by taking into account sampling fractions and response rates. Data on dialysis and kidney transplantation were obtained from the Web-Based Analysis of Dialysis Data Archives (WADDA) system and the Japanese Renal Transplant Registry.
resultsAmong 11,690 departments, 2,148 were selected (nephrology, n = 842; urology, n = 678; pediatrics, n = 628). The response rate was 32.9%. In 2022, the estimated number of patients with ADPKD not receiving KRT was 40,901 (95% confidence interval [CI], 29,543-52,259), corresponding to 32.7 per 100,000 population (1 in 3,055 individuals). Additionally, 12,487 patients with polycystic kidney disease (PKD) were receiving dialysis and 130 underwent kidney transplantation in 2022. After incorporating these data, the total population potentially representing ADPKD was estimated at 53,518 (42.8 per 100,000 population; 1 in 2,335 individuals).
conclusionsThis nationwide survey provides updated epidemiological estimates of ADPKD. Although registry data on KRT may not exclusively represent ADPKD, our findings suggest a higher disease burden than previously recognized, with prevalence consistent with estimates reported in other countries.
Indexed as
Identifiers
42189409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.